OR AKIVA, Israel, Jan. 13 /PRNewswire/ -- A new technology developed by Israeli dermatologists that has been proven safe and effective in treating psoriasis, vitiligo, atopic dermatitis and leukoderma has been cleared by the U.S. Food and Drug Administration to be marketed in this country.
MultiClear(TM), manufactured by CureLight Ltd of Or Akiva, Israel, is the first computer-controlled, targeted phototherapy system which utilizes both UVB and UVA rays. It will be widely available in the U.S. by March 2004, according to company officials.
"This system is a breakthrough treatment for psoriasis, vitiligo, atopic dermatitis and leukoderma," said Dr. Yoram Harth, medical director of CureLight.
"It is an effective non-drug alternative, combining the emissions of UVB and UVA from a single optical delivery system, allowing optimal high- intensity, targeted UV band selection for the treatment of these common skin disorders. It protects patients from exposing their entire bodies to harsh and risky treatments of the past," he said.
"Oral tablets, injections, or full-body light boxes cannot zero in on the affected areas, and thus they run the risk of harming the patient systemically or damaging other parts of the skin. Our technology acts only on the affected area," said Harth. "The MultiClear's(TM) computerized system allows the exact matching of wavelengths and doses to optimally treat specific skin disorders."
Dr. David J. Friedman, board-certified dermatologist and former Brown University assistant professor, currently uses MultiClear(TM) for his patients. He said, "It's safe, responsive and gets good aesthetic results as well. The choice between using UVB, UVA or tailored combinations of UVB and UVA in one system results in fast improvement of psoriasis, and repigmentation of hypopigmented lesions such as vitiligo and stretch marks. In some vitiligo patients repigmentation may start after the fourth treatment. Typical treatment lasts about five minutes and that's another real plus. Usually less than 10 treatments are needed."
Psoriasis is one of most common skin disorders treated by MultiClear(TM). It affects more than 7 million people worldwide and 200,000 cases are diagnosed each year in the U.S. alone. Current therapies include prolonged use of topical creams, full-body lightbox treatments repeated 30-40 times or life-long weekly injections.
Vitiligo is a pigmentation disorder affecting roughly 50 million people or about two percent of the world's population. Atopic dermatitis is a common eczema disorder that also affects millions, usually appearing first in childhood and then persisting throughout an adult's life. Leukoderma or hypopigmented skin appears in stretch marks and acne and surgical scars, and cannot be treated effectively topically or systemically.
MultiClear(TM) will be featured at a forum sponsored by the Aesthetic Buyers Guide, concurrent with the American Academy of Dermatology's annual meeting in Washington, D.C., February 9.
CureLight Ltd is a leader in the development, manufacturing and marketing of technologically advanced, effective and safe phototherapy systems for key medical disorders. CureLight has developed the first light-based systems to ever receive FDA treatment of moderate inflammatory acne. ClearLight(R), the company's award-winning product, is the first light-based, FDA-approved acne treatment device to be introduced to the U.S. market. iClear(TM), another CureLight Ltd product, is also approved by the FDA for moderate inflammatory acne and is now being marketed to physicians and Medi-Spas around the world. More than 600 clinics worldwide are currently using ClearLight(R) and iClear(TM).
For additional information visit the web site at http://www.curelight.com/ or call 888-287-3548.